Silver Book Fact

Anti-VEGF Letter Improvement

Fact image

An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.

Brown D, Nguyen Q, Marcus D, Boyer D, et al. Long-Term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-month results from two phase III trials: RISE and RIDE. Ophthalmol. 2013. http://www.aaojournal.org/article/S0161-6420(13)00212-1/abstract. Accessed May 17, 2016

Reference

Title
Long-Term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-month results from two phase III trials: RISE and RIDE
Publication
Ophthalmol
Publication Date
2013
Authors
Brown D, Nguyen Q, Marcus D, Boyer D, et al.
Volume & Issue
Volume 120, Issue 10
Pages
324-30
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • In a trial with 160 participants who had type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification benefited patients with respect to vascular complications and on rates…  
  • Every additional dollar spent on statin therapy for diabetes patients without cardiovascular disease has produced health gains valued between $7 and $31.  
  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.  
  • Blood Pressure Control in Patients with Diabetes
    Tight blood pressure control in type 2 diabetes patients reduced progression of DR by 34% and risk of deterioration by 47% after 9 years.  
  • Intensive Glycemic Control in People with Diabetes
    Intensive glycemic control in diabetics reduced their: Adjusted mean risk of DR by 76% Risk of progression by 54% Rates of laser surgery by 56% Risk of DME by 23%